yes now the ongoing cash for ACR is going to be compromised. If they win the appeal it's different.
Looks like Eli Lilly doesn't want to pay for the FDA safety study.
Cash backing right now is ~20c
Ann: Teva Launches Generic Version of Axiron in United States, page-11
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 144142 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 100089 | 2 |
View Market Depth
| Last trade - 10.33am 04/09/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable